After being fired, I became the light of medicine

Chapter 150 Annual Report Profit Inventory (Subscription Request)

"Dr. Mueller, Dr. Marcus, I'm going to trouble you next. We need to use this drug patent to develop a new injectable 'catalyst'. I'm sure this request is not too difficult for you."

“Okay, Mr. Zhang, this request is indeed not too difficult;

If there is no restriction on dissolution time and it is directly injected into the human body, many problems can be solved, but animal experiments and drug toxicity tests need to be repeated, which may take a long time. "

At the Tsingshan Pharmaceutical Drug Research and Development Center, the person who responded to Zhang Yang was Dr. Mueller, the former head of the "BI-Toxin Catalyst" project.

The purpose of their visit to Tsingshan Pharmaceutical was naturally to help the R&D team members of Tsingshan Pharmaceutical better understand the patent structure and drug efficacy mechanism of the "catalyst" so as to develop new drugs.

So the request proposed by Zhang Yang is reasonable.

"By the way, President Zhang, I've always heard that your company also has a drug development project for 'macromolecule toxin catalysts'. Can I learn about your project?"

"Don't worry, your research and development results must have been patented. I won't be so shameless as to steal your results. I just want to learn more."

Zhang Yang's expression suddenly became a little strange. Where did he get any "large molecule toxin catalyst" from? It was just a smokescreen.

Zhang Yang's strange expression surprised the conservative Germans, but gradually, Dr. Mueller also reacted.

His eyes suddenly widened:

"Zhang, you're not going to tell me that you never had this project from the beginning to the end?"

Zhang Yang shrugged:

"Dr. Mueller, listen to me. We did set up this project, but the progress is a little slow..."

Zhang Yang explained to Mueller with a little embarrassment.

After all, Dr. Mueller will stay at Qingshan Pharmaceutical for a year to help them understand the patent of "BI Toxin Catalyst", so he will definitely know the truth after long-term contact.
Instead of this, it is better to be honest.

Of course, he didn't care much about the BI company knowing the truth of the matter.

This is a business matter. Since we are in negotiation, it all depends on our ability. Besides, the price of 14.5 billion is too much of a loss to BI Company.

After taking Mueller and Dr. Marcus to Chengdu, the food capital, to eat delicious food for three consecutive days, Dr. Mueller had put all his dissatisfaction behind him.

With the personal guidance of two former project leaders from BI Company, the research and development of Qingshan Pharmaceutical's injectable "catalyst" project progressed rapidly.

Zhang Yang’s plan is to first use the “BI Toxin Catalyst” patent to develop an “macromolecule catalyst” for injection, and then form an AB bottle combination drug with “Kidney Toxin Clearing”.

After completing this work, we can consider integrating the effective decomposition ingredients in the "catalyst" and adding them to the "Kidney Toxin Clearer" so that the "Kidney Toxin Clearer" can decompose both small molecule toxins and large molecule toxins, thereby achieving the effect of improving the toxin clearance rate.

Of course, this is all in the future.

After arranging the direction for the next improvement of "Kidney Toxin Clearing", Zhang Yang also knew that the "Kidney Toxin Clearing" issue had come to an end. The next step was to wait for the injectable "large molecule toxin catalyst" to be launched on the market and then serve more dialysis patients.

After returning to the office from the drug research and development center and being alone, Zhang Yang finally breathed a sigh of relief.

He picked up the teacup and took a sip, then slowly walked to the window, his eyes suddenly falling on the security room not far away.

He thought of Jiang Yong.

He still remembered what Jiang Yong said to him that day in the hospital:

"Mr. Zhang, I would rather raise my two children with my own hands than rely on your mercy."

Suddenly, he felt inexplicably relieved and happy.

With "Kidney Toxin Clearing", Jiang Yong should be able to find a job he likes and raise two children with his own hands, right?

In addition to Jiang Yong, those young dialysis patients can all live a better life.

Gradually, he thought of those patients with "stage 3 kidney disease" and "stage 4 kidney disease". Now the hospital has begun to fully promote the trial of "Kidney Toxin Clearing" on stage 3 kidney disease...

If it is truly universal and has the effect of delaying or preventing the deterioration of the disease, patients suffering from "chronic kidney disease" should also be able to see their own light of hope in the midst of pessimism, right?
Being sick is not scary, what is scary is seeing no hope.

Fortunately, there is hope now.

Zhang Yang let out a breath.

Finally, he thought of the "toxic catalyst" for the acquisition of BI.

To be honest, it was just luck.

He never expected that "Kidney Toxin Clear" would have such a huge impact on the hemodialysis consumables market, and he never expected that Chengdu Third Hospital would publish an academic paper on "Kidney Toxin Clear" and "Stage III and IV Kidneys", which completely cut off the future prospects of the blood consumables market.

If not for this, BI Company would not have given up "BI-Catalyst" so easily, and I probably wouldn't have gotten such a bargain.

But no matter luck or strength, "BI-Catalyst" in my hands will always be able to better treat more kidney patients.

As he thought about it, Zhang Yang's thoughts finally fell on the amount of the negotiation.

to be frank,
He had never paid much attention to Tsingshan Pharmaceutical's annual profit before, and originally thought that the cash flow of more than 200 billion was enough.

But when it came time to actually conduct a large-scale BD transaction, I realized that I had always thought that a lot of funds would only be worth a few billion US dollars.

30 billion US dollars is an astronomical figure in other industries, but it is nothing in the pharmaceutical industry. In the past few days, he specifically checked the world's largest BD transactions last year, among which Pfizer spent 430 billion US dollars to acquire four tumor drugs from Seagen...

Not to mention Pfizer, even the domestic Hengrui Pharmaceuticals, in its transaction with Germany's Merck last year, one of the BD transactions exceeded US$40 billion.

Let’s take a look at the profits of the world’s top ten pharmaceutical companies last year.

Johnson & Johnson of the United States had revenue of US$851.6 billion and net profit of US$351 billion last year.

Pfizer of the United States had annual revenue of US$585 billion and net profit of US$316 billion.

The top ten or even top twenty pharmaceutical companies, including Roche, Novartis, Merck, and AbbVie, have revenues exceeding $150 billion.

In total, Johnson & Johnson can earn 2500 billion yuan a year.

“Qingshan Pharmaceutical may already be a first-tier pharmaceutical company in China, but it still lags far behind foreign pharmaceutical companies.”

"At least, in terms of earning ability, the gap is huge!"

"We still have a long way to go, and we still need to improve our profitability!"

Zhang Yang said silently in his heart.

Then he called the financial director Lao Qian again.

This time he didn't want to ask how much money was currently in the account, but wanted to take a closer look at the profit sources of the company's entire drug product line last year.

Lao Qian quickly came to Zhang Yang's office with detailed financial report data.

As we all know, Qingshan Pharmaceutical currently has a total of five drugs and one health product for sale.

The first one is "Qingshan Avaqubopa".

After comprehensive promotion in the pharmaceutical industry in recent years, the annual sales volume of "Qingshan Afa" has reached 350 million boxes, accounting for 62% of the market share in the entire "thrombocytopenia" drug field.

The annual sales amount was 16.8 billion and the net profit was 13.5 billion.

Zhang Yang has deep feelings for "Qingshan Afa", after all, it is the first drug launched by Qingshan Pharmaceutical.

But he also knew that because Qingshan Afa had joined the "He Miao Project", the medical insurance purchase price was 480 yuan per bottle, and there were only so many blood disease patients in China.
It would be good enough to occupy 62% of the market and make a stable profit of 13.5 billion a year.

Then, he looked at "ITG human growth hormone".

ITG human ovarian hormone can completely cure aplastic anemia and costs 2800 yuan per injection. After the first batch of aplastic anemia patients were cured in the past two years, sales began to decline significantly last year.

But this is also expected.

According to the latest statistics, the number of patients with aplastic anemia in China has dropped from 150 million to 72, most of whom are patients with common aplastic anemia.

Due to economic pressure or their own lack of attention, they resorted to taking medicine to maintain their health, which also caused ITG's sales to begin to decline.

Last year, a total of 80 doses were sold, with ten doses per person, which means that 8 patients with aplastic anemia were cured throughout the year.

Sales reached 22.4 billion yuan and net profit was 17.6 billion yuan.

"ITG Myelopoietin" is sold to Southeast Asia and the United Kingdom, and the situation in the two regions is similar to that in China.

As the first batch of patients who most urgently wanted a cure were cured, sales have dropped significantly in the past two years.

Only 6 doses of ITG myelopoietin were sold in Southeast Asia throughout the year, which means that only 6000 people received treatment in Southeast Asia.

Sales amounted to US$1.8 million and net profit was US$1.74 million, equivalent to RMB 12 billion.

Only 22 people received treatment in the UK, with profits of billion yuan.

In total, ITG human myeloid foetus contributed 51.6 billion to Tsingshan Pharmaceutical globally.

"The next one is 'Avofafovir'."

When Zhang Yang saw last year's purchase quantity, he felt a little sad and a little happy.

"Ikefenprovir", which cures hepatitis B, was purchased with special funds from the National Healthcare Security Administration and provided free of charge to hepatitis B patients after purchase.

The first batch purchased 1000 million bottles and the second batch purchased 2000 million bottles.

After purchasing nearly 6000 million bottles in the following years, the Medical Insurance Bureau's purchasing volume began to decrease.

This means that at least 3000 million hepatitis B patients have been cured. The remaining ones who did not receive the medicine for free either had a lack of information, purchased it through pharmacies themselves or for other reasons.

The bad news is that last year the Medical Insurance Bureau's purchasing quantity dropped to 1000 million bottles, with sales of only 50 billion yuan and profits of only 40 billion yuan.

Moreover, like "ITG-induced growth factor", it won't be long before the profits of "Ikeprofovir", which cures hepatitis B, will approach zero.

Seeing that it was almost impossible for the first three drugs to generate huge profits, Zhang Yang suddenly felt mixed emotions.

　-1 chapter to go, only 1 chapter left, will finish it tomorrow!
　　
　
(End of this chapter)